In this episode of the Oncology Brothers podcast, we are joined by Dr. Komal Jhaveri, a breast medical oncologist at Memorial Sloan Kettering, to discuss the evolving landscape of metastatic hormone receptor positive breast cancer, particularly focusing on low and ultra-low HER2 expression.
Key topics include:
• The significance of the DESTINY Breast-04 and DESTINY Breast-06 studies and their impact on treatment options.
• The definition and implications of low and ultra-low HER2 expression in clinical practice.
• The importance of HER2 testing and the dynamic nature of HER2 expression in tumors.
• Treatment sequencing strategies, including the use of antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (TDXd) and sasituzumab govitecan.
• Management of treatment-related toxicities, including ILD, nausea, and alopecia.
Join us for an insightful discussion that aims to keep healthcare professionals updated on the latest advancements in cancer care.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes and insights!
